UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~December~~July 19, ~~2024~~2025

Greenwich LifeSciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39555

20-5473709

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I. R. S. Employer

Identification No.)

3992 Bluebonnet Dr, Building 14

Stafford, TX 77477

(Address of principal executive offices, including ZIP code)

(832) 819-3232

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		GLSI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5 4.0701 ~~Submission~~Changes ofin ~~Matters~~Registrant’s toCertifying ~~a Vote of Security Holders~~Accountant.

On ~~December~~July 19, ~~2024~~2025, the audit committee of the Board of Directors of Greenwich LifeSciences, Inc. (the “Company”) ~~held~~approved ~~its~~the dismissal ~~Annual Meeting~~ of ~~Stockholders~~RBSM ~~(the~~LLP (“~~Annual Meeting~~RBSM”). Aas ~~total~~the ofCompany’s ~~12,848,165~~independent ~~shares~~registered ofpublic ~~common~~accounting ~~stock,~~firm ~~constituting~~and aapproved ~~quorum,~~the ~~were~~engagement of ~~represented~~MaloneBailey inLLP ~~person~~(“MaloneBailey”) oras bythe ~~valid~~Company’s ~~proxies at~~independent ~~the~~registered ~~Annual~~public ~~Meeting.~~accounting ~~The~~firm ~~final~~to ~~results~~audit ~~for~~the ~~each~~Company’s consolidated offinancial ~~the~~statements ~~matters~~for ~~submitted~~the toyear aended ~~vote~~December of31, ~~stockholders~~2025. atAccordingly, ~~the~~on ~~Annual~~July ~~Meeting~~19, as2025, ~~set~~RBSM ~~forth in~~was ~~the~~informed ~~Definitive~~that ~~Proxy~~it ~~Statement,~~would be ~~filed~~dismissed ~~with~~as the ~~Securities~~Company’s ~~and~~independent ~~Exchange~~registered ~~Commission~~public onaccounting ~~November 1~~firm, ~~2024~~effective ~~are as follows:~~immediately.

~~Proposal~~The 1.report ~~All~~ of RBSM on the ~~five~~Company’s ~~(5)~~financial ~~nominees~~statements ~~for~~as ~~director~~of ~~were~~December ~~elected~~31, to2024 ~~serve~~and ~~until~~2023, and the ~~2025~~related ~~Annual~~statements ~~Meeting~~ of ~~Stockholders~~operations, changes orin ~~until~~stockholders’ ~~their~~equity ~~respective successors~~and ~~have~~cash ~~been~~flows ~~duly~~for ~~elected~~the ~~and~~years ~~qualified~~ended December 31, or2024 ~~until~~and ~~such~~2023 ~~director’s~~did ~~earlier~~not ~~resignation,~~contain ~~removal~~an adverse opinion or ~~death.~~a ~~The~~disclaimer ~~result~~ of ~~the~~ ~~votes~~opinion, tonor ~~elect~~was ~~the~~it ~~five~~qualified ~~(5)~~or ~~directors~~modified ~~was~~ as ~~follows:~~to uncertainty, audit scope or accounting principles.

Directors	For		Against		Abstain		Broker Non Vote
David McWilliams		7,824,313		0		408,663		1,004,439
Snehal S. Patel		8,052,306		0		184,934		1,000,175
Eric Rothe		7,849,736		0		383,240		1,004,439
F. Joseph Daugherty, M.D.		7,987,061		0		245,915		1,004,439
Kenneth Hallock		7,852,855		0		380,121		1,004,439

During the fiscal years ended December 31, 2024 and 2023 there have been no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for the material weaknesses in the Company’s internal control over financial reporting described in Part II, Item 9A, “Controls and Procedures,” in the Company’s annual reports on Form 10-K for the years ended December 31, 2024 and 2023, respectively and in Part I, Item 4, “Controls and Procedures,” in the Company’s quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, September 30, 2024 and March 31, 2025 filed with the SEC on May 20, 2024, August 14, 2024, November 14, 2024 and May 20, 2025, respectively. The Audit Committee has discussed the material weaknesses in the Company’s internal control over financial reporting with RBSM and has authorized RBSM to respond fully to the inquiries of MaloneBailey, the Company’s new independent registered public accountants, concerning such weakness.

~~Proposal~~During 2.the ~~The~~years ~~appointment~~ended ofDecember ~~RBSM~~31, ~~LLP~~2024 asand 2023 and through July 19, 2025, there were no disagreements between the Company’s ~~independent~~and ~~registered~~RBSM ~~public~~on any matter of accounting ~~firm~~principles ~~for~~or ~~its~~practices, ~~fiscal~~financial ~~year~~statement ~~ended~~disclosure, ~~December~~or auditing scope or procedure, which disagreements, if 31not resolved to the satisfaction of RBSM, ~~2024~~would ~~was~~have ~~ratified~~caused ~~and~~it ~~approved~~to bymake reference to the ~~stockholders~~subject bymatter of the ~~votes~~disagreement ~~set~~in ~~forth~~connection with inits ~~the~~report ~~table~~covering ~~below:~~such period.

For				Against				Abstain				Broker Non Vote
	9,224,694				10,077				2,644				0

During the years ended December 31, 2024 and 2023 and through July 19, 2025, the date the audit committee of the Board approved the engagement of MaloneBailey as the Company’s independent registered public accounting firm, neither the Company nor anyone on the Company’s behalf consulted with MaloneBailey regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company by the Company that the Company concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as that term is described in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act, or a reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act.

~~Proposal~~The 3. Company ~~The~~provided ~~amendment~~RBSM towith ~~the~~a ~~Company’s~~copy ~~2019~~of ~~Equity~~the ~~Incentive~~foregoing ~~Plan~~disclosures prior to ~~increase~~ the ~~number~~filing of ~~shares~~this Report ofand ~~common~~requested ~~stock~~that ~~reserved~~RBSM ~~for issuance~~furnish ~~under~~the ~~such~~Company ~~plan~~with toa ~~4,000,000~~letter ~~shares~~addressed ~~from~~to ~~1,500,000~~the ~~shares~~SEC ~~was~~stating whether ~~ratified~~it ~~and~~agrees ~~approved~~with by the ~~stockholders~~statements made by the ~~votes~~Company set forth above. A copy of RBSM’s in letter, ~~the~~dated ~~table~~July ~~below:~~22, 2025, is attached as Exhibit 16.1 to this Report.

For				Against				Abstain				Broker Non Vote
	8,067,672				164,730				5,043				999,970

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

16.1		Letter from RBSM LLP to the Securities and Exchange Commission dated July 22, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Greenwich LifeSciences, Inc.
Date: December 19, 2024	By:	/s/ Snehal Patel
Date: July 24, 2025	By:	/s/ Snehal Patel
		Snehal Patel
		Chief Executive Officer

-3-

Filing Compare · Greenwich LifeSciences, Inc.